Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
Proper safety protocols extend beyond storage to include injection techniques and administration procedures
Injection anxiety, refrigeration requirements, and needle disposal create barriers that prevent people from trying effective medications
Ozempic can [slow down] stomach emptying, which slows calorie absorption, and may lead to a sense of fullness, so many who take it lose weight, she explains
In the SURMOUNT-1 trial, participants without diabetes achieved average weight loss of 15-20% of baseline body weight over 72 weeks at the highest doses, with somewhat lower reductions observed in people with type 2 diabetes
US$ 23.16
US$ 21.68
US$ 20.30
